Equities analysts expect CymaBay Therapeutics Inc (NASDAQ:CBAY) to report earnings per share (EPS) of ($0.12) for the current quarter, Zacks reports. Two analysts have made estimates for CymaBay Therapeutics’ earnings. The lowest EPS estimate is ($0.22) and the highest is $0.03. CymaBay Therapeutics reported earnings of ($0.30) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 60%. The firm is scheduled to issue its next quarterly earnings report on Thursday, March 22nd.

On average, analysts expect that CymaBay Therapeutics will report full-year earnings of ($0.82) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.62). For the next fiscal year, analysts forecast that the company will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.02) to ($0.82). Zacks’ EPS calculations are an average based on a survey of research analysts that cover CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same period in the previous year, the company posted ($0.25) earnings per share.

Several research firms have weighed in on CBAY. Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, September 26th. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, September 18th. Leerink Swann reiterated a “buy” rating and set a $16.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Oppenheimer set a $15.00 price objective on CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $14.50.

CymaBay Therapeutics (NASDAQ CBAY) traded up $0.42 during mid-day trading on Wednesday, reaching $9.42. The company’s stock had a trading volume of 632,577 shares, compared to its average volume of 590,400. The company has a quick ratio of 7.39, a current ratio of 7.39 and a debt-to-equity ratio of 0.04. The company has a market cap of $413.20, a PE ratio of -9.33 and a beta of 1.82. CymaBay Therapeutics has a 1 year low of $1.46 and a 1 year high of $9.79.

In other news, Director Carl Goldfischer sold 18,000 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $8.66, for a total transaction of $155,880.00. Following the sale, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $77,940. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Kurt Von Emster sold 173,192 shares of the stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $9.41, for a total value of $1,629,736.72. Following the sale, the director now directly owns 90,000 shares in the company, valued at $846,900. The disclosure for this sale can be found here. Over the last three months, insiders have sold 300,449 shares of company stock worth $2,797,929. 15.10% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new stake in shares of CymaBay Therapeutics during the 3rd quarter worth $1,218,000. Iguana Healthcare Management LLC boosted its stake in CymaBay Therapeutics by 138.1% in the third quarter. Iguana Healthcare Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock valued at $2,015,000 after buying an additional 145,000 shares in the last quarter. Crestline Management LP acquired a new stake in CymaBay Therapeutics in the third quarter valued at about $841,000. Perceptive Advisors LLC acquired a new stake in CymaBay Therapeutics in the third quarter valued at about $18,948,000. Finally, Boothbay Fund Management LLC acquired a new stake in CymaBay Therapeutics in the third quarter valued at about $404,000. 69.12% of the stock is currently owned by institutional investors.

WARNING: “Zacks: Brokerages Expect CymaBay Therapeutics Inc (CBAY) Will Post Earnings of -$0.12 Per Share” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/03/zacks-brokerages-expect-cymabay-therapeutics-inc-cbay-will-post-earnings-of-0-12-per-share.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.